Top

Published in:

01-08-2013 | Review

Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research

Authors: Michaela S. Tracy, Shoshana M. Rosenberg, Laura Dominici, Ann H. Partridge

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Abstract

Recent studies have revealed increasing rates of contralateral prophylactic mastectomy (CPM) among women with unilateral early stage breast cancer. This trend has raised concerns, given the lack of evidence for a survival benefit from CPM and the relatively low risk of contralateral breast cancer for most women in this setting. In this article, we review available data regarding the value of CPM, predictors, and outcomes related to CPM, and areas for future research and potential intervention.

Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209PubMedCrossRef

Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27(9):1362–1367PubMedCrossRef

Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol 17(10):2554–2562PubMedCrossRef

Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180(6):439–445PubMedCrossRef

McLaughlin CC, Lillquist PP, Edge SB (2009) Surveillance of prophylactic mastectomy: trends in use from 1995 to 2005. Cancer 115(23):5404–5412PubMedCrossRef

Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM (2009) Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol 16(10):2691–2696PubMedCrossRef

King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29(16):2158–2164PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467

Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132):930–942

10.

Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275–4286PubMedCrossRef

11.

Bedrosian I, Hu CY, Chang GJ (2010) Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401–409PubMedCrossRef

12.

Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A (2012) Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 19(8):2600–2606PubMedCrossRef

13.

van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van’t Veer LJ, Tollenaar RA (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93(3):287–292PubMedCrossRef

14.

Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 11:CD002748PubMed

15.

Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F (2010) Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 3(8):1026–1034CrossRef

16.

Nekhlyudov L, Bower M, Herrinton LJ, Altschuler A, Greene SM, Rolnick S, Elmore JG, Harris EL, Liu A, Emmons KM, Fletcher SW, Geiger AM (2005) Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr 35:55–60PubMedCrossRef

17.

Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM (2009) Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 16(10):2697–2704PubMedCrossRef

18.

Sorbero ME, Dick AW, Beckjord EB, Ahrendt G (2009) Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 16(6):1597–1605PubMedCrossRef

19.

Kwong A, Chu AT (2012) What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing. Asian Pac J Cancer Prev 13(5):2241–2247PubMedCrossRef

20.

Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA (2012) Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol 19(10):3246–3250PubMedCrossRef

21.

Hawley ST, Jagsi R, Morrow M, Katz SJ (2011) Correlates of contralateral prophylactic mastectomy in a population-based sample. J Clin Oncol 29: (suppl; abstr 6010)

22.

Rosenberg SM, Tracy M, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH (2013) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: A cross-sectional survey. Ann Intern Med (in press)

23.

Abbott A, Rueth N, Pappas-Varco S, Kuntz K, Kerr E, Tuttle T (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18(11):3129–3136PubMedCrossRef

24.

Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, Borgen PI (1999) Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6(6):546–552PubMedCrossRef

25.

Losken A, Carlson GW, Bostwick J 3rd, Jones GE, Culbertson JH, Schoemann M (2002) Trends in unilateral breast reconstruction and management of the contralateral breast: the Emory experience. Plast Reconstr Surg 110(1):89–97PubMedCrossRef

26.

Musiello T, Bornhammar E, Saunders C (2012) Breast surgeons’ perceptions and attitudes towards contralateral prophylactic mastectomy. ANZ J Surg. doi:10.1111/j.1445-2197.2012.06209.x PubMed

27.

Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, Ames FC, Schusterman MA, Singletary SE (1998) Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early stage breast cancer. Ann Surg Oncol 5(6):529–538PubMedCrossRef

28.

Fisher ER, Fisher B, Sass R, Wickerham L (1984) Pathologic findings from the National surgical adjuvant breast project (Protocol No. 4). XI. Bilateral breast cancer. Cancer 54(12):3002–3011PubMedCrossRef

29.

Adami HO, Bergstrom R, Hansen J (1985) Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 55(3):643–647PubMedCrossRef

30.

Harris RE, Lynch HT, Guirgis HA (1978) Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 60(5):955–960PubMed

31.

Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351(9099):316–321PubMedCrossRef

32.

Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG (1999) Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17(11):3396–3402PubMed

33.

McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19(19):3938–3943PubMed

34.

Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD (2007) Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 104(3):321–329PubMedCrossRef

35.

Arrington A, Tuttle T (2010) Author Reply: contralateral prophylactic mastectomy overtreatment: Expectations from personal genomics for tailored breast cancer surgery. Ann Surg Oncol 17:940CrossRef

36.

Hawley S, Jagsi R, Katz S (2012) Is contralateral prophylactic mastectomy (CPM) overused? Results from a population-based study. J Clin Oncol 30:(suppl 34; abstr 26)

37.

Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A (2013) Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140(1):135–142PubMedCrossRef

38.

Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ, Hartmann LC, Frost MH (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709PubMedCrossRef

39.

Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IL, Altschuler A, Rolnick SJ, Harris EL, Greene SM, Elmore JG, Emmons KM, Fletcher SW (2006) Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 24(9):1350–1356PubMedCrossRef

40.

Rolnick SJ, Altschuler A, Nekhlyudov L, Elmore JG, Greene SM, Harris EL, Herrinton LJ, Barton MB, Geiger AM, Fletcher SW (2007) What women wish they knew before prophylactic mastectomy. Cancer Nurs 30(4):285–291 quiz 292–283PubMedCrossRef

41.

Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM, Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23(31):7849–7856PubMedCrossRef

42.

Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y (2012) Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2 years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer 48(17):3150–3156PubMedCrossRef

43.

Tuli R, Chandra RA, Sugar E, Christodouleas JP, Flynn RA, Usuki KY, Brill KL, Rosenberg AL (2010) Patient decision making, satisfaction, and quality of life following contralateral prophylactic mastectomy. J Clin Oncol 28(15):19160

44.

Stover AC, Warren PA, Foster RD, Esserman LJ, Alvarado MD, Ewing CA, Hwang ES (2012) Impact of contralateral prophylactic mastectomy on surgical outcomes. Cancer Res 71:PD02-01CrossRef

45.

Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355(9217):1822PubMedCrossRef

46.

Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC (2011) Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol 29(22):2993–3000PubMedCrossRef

47.

Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (<or = 40 years) with breast cancer. J Surg Oncol 100(3):248–251PubMedCrossRef

48.

Vilholm OJ, Cold S, Rasmussen L, Sindrup SH (2008) The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer 99(4):604–610PubMedCrossRef

49.

Sivell S, Edwards A, Manstead AS, Reed MW, Caldon L, Collins K, Clements A, Elwyn G (2012) Increasing readiness to decide and strengthening behavioral intentions: evaluating the impact of a web-based patient decision aid for breast cancer treatment options (BresDex: www.bresdex.com). Patient Educ Couns 88(2):209–217

50.

Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK (2012) Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30(5):497–506PubMedCrossRef

51.

Peate M, Meiser B, Cheah BC, Saunders C, Butow P, Thewes B, Hart R, Phillips KA, Hickey M, Friedlander M (2012) Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early stage breast cancer. Br J Cancer 106(6):1053–1061PubMedCrossRef

Title: Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research
Authors: Michaela S. Tracy
Shoshana M. Rosenberg
Laura Dominici
Ann H. Partridge
Publication date: 01-08-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2643-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions

Clinical outcomes following nipple–areola-sparing mastectomy with immediate implant-based breast reconstruction: a 12-year experience with an analysis of patient and breast-related factors for complications

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics

Hospital and surgeon caseload are associated with risk of re-operation following breast-conserving surgery

CX3CL1 expression is associated with poor outcome in breast cancer patients

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer